In the last trading session, 1.09 million shares of the Arbutus Biopharma Corp (NASDAQ:ABUS) were traded, and its beta was 2.05. Most recently the company’s share price was $2.75, and it changed around $0.11 or 4.17% from the last close, which brings the market valuation of the company to $495.50M. ABUS currently trades at a discount to its 52-week high of $3.29, offering almost -19.64% off that amount. The share price’s 52-week low was $1.69, which indicates that the current value has risen by an impressive 38.55% since then. We note from Arbutus Biopharma Corp’s average daily trading volume that its 3-month average coming to 1.41 million.

Arbutus Biopharma Corp stock received a consensus recommendation rating of Buy, based on a mean score of 1.40. If we narrow it down even further, the data shows that 0 out of 7 analysts rate the stock as a Sell; another 2 rate it as Overweight. Among the rest, 1 recommended ABUS as a Hold, whereas 4 deemed it a Buy, and 0 rated it as Underweight. Arbutus Biopharma Corp is expected to report earnings per share of $Arbutus Biopharma Corporation for the current quarter.

Arbutus Biopharma Corp (NASDAQ:ABUS) trade information

Instantly ABUS has showed a green trend with a performance of 4.17% at the end of last trading. The performance over the last five days has remained in the red territory. The company’s shares are currently up 10.00% year-to-date, but still down -5.82% over the last five days. On the other hand, Arbutus Biopharma Corp (NASDAQ:ABUS) is 10.00% up in the 30-day period.

The consensus price target as assigned by Wall Street analysts is $8.5, which translates to bulls needing to increase their stock price by 67.65% from its current value. Analyst projections state that ABUS is forecast to be at a low of $8.5 and a high of $8.5.

Arbutus Biopharma Corp (ABUS) estimates and forecasts

Arbutus Biopharma Corp share prices are performing particularly well not compared to other companies within the same industry. As is evident from the statistics, the company’s shares have risen 58.05 percent over the past six months and at a 11.36% annual growth rate that is well below the industry average of 13.00%.

Looking at the company’s year-over-year earnings, the past five years showed a positive earnings growth rate of 18.41%.

ABUS Dividends

Arbutus Biopharma Corp’s next quarterly earnings report is expected to be released in May.